At the IGTP TODAY

News

- Research

The IGTP and the Èpica Foundation of the Fura dels Baus present the results of the workshop ‘Complex Systems’

Last week the preliminary results of a collaboration between the scenic arts and science, or in other words, between the Èpica Foundation of the Fura dels Baus and the IGTP were presented. The workshop and the resulting performance took place last November and now the researchers are processing the data collected from the experience, which will be useful for their respective research projects.

- Research

Scientists from Germans Trias publish data on the negative effects of vaping on the immune response to tuberculosis infections

Scientists from the Innovation in Respiratory Infections and Tuberculosis Diagnosis Group at the IGTP and the Microbiology Service at the Germans Trias Hospital have published a paper in PLOS One on negative effects of vapour from e-cigarettes on the immune response against tuberculosis (TB). The results describe the effect of the vapour specifically on TB infection and they support the need for policies to reduce exposure to both smoke and e-vapour as part of strategies to control TB.

- Research

The Can Ruti Rare Diseases Workshop shows the strength of multidisciplinary work on the campus

This years' edition of the Workshop on Rare Diseases took place at the IGTP this Thursday with the title 'A Multidisciplinary Approach to Rare Diseases' timed for the International Day for Rare Diseases, celebrated this year on 29 February. The key to improving the management of this type of disease is dialogue between different specialty areas and a much more global approach. This must be coupled with the inclusion of research staff when deciding on the lines of research to be advanced.

- Campus Can Ruti, Research

New European initiative, RECOGNISED, will determine the usefulness of the retina as a tool for identifying people with type 2 diabetes and cognitive impairment

The IGTP is participating in this recently launched EU-funded project to explore the biological pathways that may link the alterations observed in the retina with those present in the brain in people with type 2 diabetes (T2D). In this way, the RECOGNISED project hopes to use the eye as if it was a window into the brain.

- Research

The EU awards 16 million euros to Can Ruti for two Projects on infectious diseases coordinated by IrsiCaixa and the Germans Trias i Pujol Research Institute

The European Union has granted 10 projects in all of Europe in the area "prevention, treatment and cure of infectious diseases" in the last call for the Horizon 2020 Programme. The only two to come to Spain have been awarded to institutions on Can Ruti Campus (Badalona). One of the studies will investigate the role of the intestinal microbiome in cases of HIV infection and the other the potential of anti-inflammatories as adjuvant therapy for tuberculosis.

- Research

The #hepCityFree movement has been launched to make cities the key area for the definitive eradication of hepatitis C

The movement is being led by some of the top experts on hepatitis C and public health at national level, including Dr Elisa Martró, leader of the Clinical Virology and New Diagnostic Tools Group at the IGTP and the Microbiology Service at the Germans Trias Hospital. The experts are aiming at cities, where there are higher numbers of people living with the virus and they are also where most new infections occur.

- Research

The Immunopathology Group part of a European consortium developing cellular immunotherapies

The official kick-off meeting of the consortium INsTRuCT (INnovative Training in myeloid Regulatory Cell Therapy) took place this week in Regensburg, Germany and Dr Eva Martínez-Cáceres, Head of the Immunopathology Research Group, took part. InsTRuCT is a Marie Skłodowska-Curie Action, within the Horizon 2020 research funding programme. Its members are European researchers from the areas of academia and business and their aim is to carry out basic and clinical research to develop immunotherapies based on myeloid regulatory cells (MRC).